Low-Frequency Repetitive Transcranial Magnetic Stimulation over Right Dorsolateral Prefrontal Cortex in Parkinson’s Disease

Table 1

Demographic and baseline characteristics of participants.

	Active group (n = 19)	Sham group (n = 14)	value
Age, y	60.58 (9.21)	61.57 (13.25)	0.80
Gender, F/M	8/11	7/7	0.65^a
Disease duration, m	70.37 (52.26)	68.57 (45.29)	0.91
Educated year, y	8.53 (2.07)	7.71 (2.27)	0.29^a
H-Y stage	2 (1.5,2.5)	2.25 (1.75, 3.0)	0.38^b
LED, mg	473.94 (214.79)	516.07 (210.22)	0.58
UPDRS part III	27.84 (8.96)	29.00 (13.16)	0.77
UPDRS	48.58 (15.90)	43.71 (19.13)	0.43
NMSQ	12.05 (4.61)	8.79 (5.16)	0.07
HRSD	13.26 (6.90)	15.86 (7.12)	0.30
PSQI	9.63 (4.87)	7.57 (3.25)	0.18
MoCA	24.37 (3.51)	22.64 (3.15)	0.16

Data are presented as mean (SD) or median (Q₂₅, Q₇₅). Abbreviations: H-Y stage: Hoehn and Yahr stage; LED: levodopa equivalent dose; UPDRS: Unified Parkinson’s Disease Rating Scale; NMSQ: Nonmotor Symptom Questionnaire; HRSD: Hamilton Rating Scale for Depression; PSQI: Pittsburgh Sleep Quality Index; MoCA: Montreal Cognitive Assessment. ^a test; ^bMann–Whitney U test.